Modulation of the bronchial inflammation in sensitized guinea-pigs by FK506, nedocromil sodium and dexamethasone

J.R. Lapa e Silva*, C. Ruffié**, B.B. Vargaftig**, M. Pretolani**


ABSTRACT: Guinea-pigs sensitized by a subcutaneous injection of ovalbumin in Al(OH)₃ and boosted 2 weeks later exhibit marked bronchial hyperresponsiveness to various agonists and intense bronchial wall infiltration by CD4⁺ T-lymphocytes and eosinophils. We have compared the effect of FK506, a novel immunosuppressive agent, on the mucosal infiltration by T-cells and eosinophils with the well established drugs, nedocromil sodium and dexamethasone.

Sensitized Hartley guinea-pigs were treated subcutaneously for 5 days with FK506 (100 µg·kg⁻¹ daily), nedocromil sodium (30 µg·kg⁻¹ daily), or dexamethasone (200 µg·kg⁻¹ daily). On the day of the experiment, i.e. one week after the booster injection of antigen, the animals were killed, the lungs dissected, frozen and cryostat sections stained by immunohistochemical methods using monoclonal antibodies specific for total T-lymphocytes, CD4⁺ and CD8⁺ T-cells. Cyanide-resistant eosinophil peroxidase activity was used to stain the eosinophils. Sections were coded and positive cells enumerated in the lamina propria and adventitia of the bronchi.

Sensitized and antigen-stimulated vehicle-treated guinea-pigs showed marked infiltration of the bronchial wall by CD4⁺ T-lymphocytes and eosinophils compared with sensitized, non-antigen stimulated animals. As compared to vehicle, FK506 or dexamethasone abolished the T-cell/eosinophil invasion in the bronchial wall, whereas nedocromil sodium was ineffective in protecting the lungs from T- lymphocyte or eosinophil infiltration.

We conclude that both FK506 and dexamethasone are effective in curtailing bronchial inflammation in allergic guinea-pigs, whereas nedocromil sodium did not resolve the inflammation associated with T-lymphocytes or eosinophils.


Bronchial mucosal inflammation is recognized as one of the main events associated with bronchial hyperresponsiveness and asthma [1]. Many cells and their secreted products participate in the pathogenesis of the disease [2], but it is now well-established that co-operation between eosinophils and T-lymphocytes is necessary for its development [3]. We have employed animal models to investigate the relationship between both cell types in the pathogenesis of bronchial inflammation and hyperresponsiveness. In particular, we demonstrated that isolated lungs from guinea-pigs sensitized with subcutaneous (s.c.) injections of ovalbumin at days 0 and 14, and killed on day 21 exhibit marked bronchopulmonary responsiveness to various agonists [4], as well as a marked infiltration of the bronchial wall by CD4⁺ T-lymphocytes and eosinophils [5]. Furthermore, when challenged with antigen on day 21, other signs of intense bronchial inflammation, such as marked bronchial epithelial shedding, were found in sensitized and antigen-stimulated animals but not in sensitized, non-antigen-stimulated guinea-pigs, where CD4⁺ T-lymphocytes had not been increased [5].

A drug recently introduced in asthma therapy is nedocromil sodium. In our experimental setting, nedocromil sodium demonstrated anti-inflammatory properties. Indeed, using the presently described model of ovalbumin-sensitized guinea-pigs we found that a 1 week treatment with nedocromil sodium markedly reduced the proportion of eosinophils in the bronchoalveolar fluid (BALF) of sensitized and antigen-stimulated animals, a phenomenon accompanied by a reduction in bronchopulmonary hyperresponsiveness [6].

FK506 is a newly developed immunosuppressant that has been extensively investigated, not only for its ability to reduce rejection of allograft transplants, but also for its anti-inflammatory activities in immunological conditions [7].

In the present study, using ovalbumin-sensitized and antigen-stimulated guinea-pigs, we investigated the modulatory activity of FK506 on allergic bronchial inflammation.
and compared it with the effects of the well-established drugs, nedocromil sodium and dexamethasone.

Materials and methods

Animals and sensitization procedure

Male Hartley guinea-pigs (Charles Rivers, St. Aubin les Elbeuf, France) weighing 400–600 g were actively sensitized on day 0 by a s.c. injection of 0.5 ml of 0.9% NaCl (saline, Merck, Darmstadt, Germany), containing 10 µg of ovalbumin (Miles, Naperville, IL, USA) dispersed in 1 mg Al(OH)₃ (Merck). On day 14, the animals were either administered a booster injection under the same conditions, or received the adjuvant only. All animals were killed on day 21.

This immunization procedure promotes the production of high titres of specific homocytotropic immunoglobulin G (IgG) antibodies, as evaluated by passive cutaneous anaphylaxis [4].

Drug treatments

Two experimental procedures were used, firstly to investigate the effects of FK506 and secondly to examine the anti-inflammatory properties of dexamethasone and nedocromil sodium. In preliminary experiments, sensitized guinea-pigs were treated s.c. with either 1 mg or 100 µg·kg⁻¹ daily FK506 for 5 days. As both of these FK506 dosages are effective in inhibiting the effects resulting from the booster injection, such as inhibition of T-lymphocyte and eosinophil infiltration in the bronchial mucosa, the lower dose regimen was employed in this study (data not shown). The drug was prepared according to instructions of the manufacturer: 10 mg FK506 were dissolved in 1 mL ethanol (Merck, Darmstadt, Germany) and 0.5 mL of this solution was mixed with 0.1 mL Tween 80 (Fluka Chemika, Buchs, Switzerland). The whole mixture was diluted with 4.4 mL of sterile saline to give a final concentration of 1 mg·mL⁻¹ FK506. Dilutions were performed in saline. Control animals received similar amounts of vehicle only, i.e. ethanol/Tween 80 injected by s.c. route.

For nedocromil sodium treatment, guinea-pigs received 30 mg·kg⁻¹ daily of the drug, injected s.c. for 5 days, and control animals received similar amounts of sterile saline. This dose and administration regimen for nedocromil sodium was selected on the basis of a previously reported study, using the same sensitization procedure [6].

Finally, a group of sensitized guinea-pigs were treated s.c. with 20 mg·kg⁻¹ daily dexamethasone phosphate (Sigma Chemical Co., St. Louis, MO, USA) for 5 days and the controls received similar amounts of sterile saline.

Handling of samples

The animals were terminally anaesthetized with 60 mg·kg sodium pentobarbital, (Clin-Midy, Montpellier, France) injected intraperitoneally, exsanguinated via the abdominal aorta, and the contents of the thoracic cavity resected "en bloc". The lungs were inflated via the trachea with 3 mL of Histocon® (Polysciences, Warrington, PA, USA), the lobes dissected and mounted in optimum cutting temperature compound (BDH, Poole, UK), and snap-frozen in isopentane (Prolabo, Paris, France) cooled by liquid nitrogen. The frozen blocks were stored at -80°C prior to use. Cryostat sections were collected on glass slides coated with poly-L-lysine (Sigma), fixed in chloroform-acetone (Merck) vol/vol for 10 min, and stored at -20°C prior to use.

Immunohistochemistry

Consecutive sections of each lobe were stained with the following monoclonal antibodies: H159 for mature T-lymphocytes, staining between 70–90% of mature T-cells [8]; H155 recognizing CD4⁺ T-cells [9]; CT6 for CD8⁺ T-cells [10]. For the mouse antibody (CT6), alkaline phosphatase anti-alkaline phosphatase (APAAP) staining procedure was performed as described previously [5], using rabbit immunoglobulin (Ig) to mouse Ig (Z259, Dakopatts a/s, Copenhagen, Denmark) and mouse APAAP (D651, Dakopatts a/s), followed by incubation with the substrate Fast Red TR (Sigma) and naphthol AS MX phosphate (Sigma), and light haematoxylin counterstaining. For the rat monoclonal antibodies (H159 and H155), APAAP was also performed, using rabbit Ig to rat Ig (Z455, Dakopatts a/s) and rat APAAP (D488, Dakopatts a/s), followed by similar development. A histological method for cyanide-resistant eosinophil peroxidase (EPO) activity, employing diaminobenzidine (Merck), H₂O₂ and potassium cyanide (Merck) was used to stain eosinophils [11].

Quantitation and statistics

At least two sections were stained with each antibody or the EPO technique, coded and read in a "blind" fashion. The positive cells were enumerated in two histological compartments of the bronchial wall, the bronchial lamina propria, between the basal lamina and the smooth muscle, and in the adventitia, between the smooth muscle and the cartilage. Cells were not quantitated in the epithelial compartment due to frequent shedding of the epithelium. The area of each compartment was calculated by using an eyepiece graticule of known area. This area and the number of positive cells were determined on each microscopic field, and at least 10 high power fields were analysed per compartment. The results for each slide were presented as the number of positive cells per unit area (6.25×10⁴ µm², the total area of the graticule). The results were presented as mean±SEM and the groups compared by one-way analysis of variance, followed by the multiple range test of Student-Newman-Keuls, using the statistical software SPSS. Differences between groups were considered statistically significant when p was equal or less than 0.05.
Effects of FK506 on cellular infiltration in the bronchial mucosa

The effects of the FK506 or its vehicle on T-lymphocytes, T-cell subsets and eosinophils were analyzed in the bronchial lamina propria and adventitia of sensitized guinea-pigs. The booster injection of antigen to sensitized guinea-pigs was followed by a marked T-lymphocyte and eosinophil infiltration in the bronchial mucosa. T-cell influx was due mostly to CD4+ T-lymphocyte recruitment (fig. 1). Increase in the number of CD8+ T-lymphocytes in the bronchial lamina propria was not detected (fig. 1). Cellular infiltration was more intense in the lamina propria than in the adventitia (figs. 1 and 2). Treatment of the sensitized animals with 100 µg·kg⁻¹ daily FK506 for 5 days resulted in suppression of T-lymphocyte and subset recruitment in both bronchial compartments examined (fig. 1). It is noteworthy that FK506 reduced cell counts, including CD8+ T–cells, below the basal values observed in control unboosted animals (fig. 1).

Sensitized and antigen stimulated, vehicle-treated guinea-pigs failed to show a significant increment in the numbers of EPO+ cells in the bronchial mucosa, compared with non-antigen-stimulated animals (fig. 2). However, a marked and significant reduction in the number of positive cells was noted in the bronchial lamina propria of animals treated with FK506, compared with antigen-stimulated vehicle-treated guinea-pigs. Indeed, EPO+ cell counts were lower than those found in the bronchial tissue from non-antigen stimulated vehicle-injected guinea-pigs (fig. 2).
Effects of nedocromil sodium and dexamethasone on cellular infiltration in the bronchial mucosa

The effects of nedocromil sodium and of the glucocorticosteroid dexamethasone or their vehicle, saline, on T-lymphocytes, T-cell subsets and eosinophils were analysed in the bronchial wall compartments of sensitized and antigen-stimulated guinea-pigs (figs. 3 and 4). No differences were observed in the total T-lymphocyte or CD4+ and CD8+ T-cell numbers when nedocromil sodium (30 mg·kg⁻¹ daily for 5 days) and saline-treated control animals were compared (fig. 3). However, dexamethasone (20 mg·kg⁻¹ daily for 5 days) suppressed total T-cell and CD4+ T-lymphocyte recruitment both in the bronchial lamina propria and the adventitia (fig. 3). The number of CD8+ T-lymphocytes did not vary significantly in the different groups (fig. 3).

Figure 4 shows the results for EPO+ cells, i.e. eosinophils, in the mucosal compartments. Again, dexamethasone markedly reduced the number of eosinophils infiltrating the bronchial lamina propria (p<0.05). Reduction in eosinophils in the mucosa was not found in animals treated with nedocromil sodium.

Figures 5 and 6 illustrate the effects of the different anti-inflammatory drugs described above on antigen-induced cellular recruitment in the bronchial lamina propria.

Fig. 3. – Distribution of T-lymphocytes and subsets in the bronchial wall compartments a) lamina propria and b) adventitia from: sensitized non-antigen-stimulated vehicle-injected guinea-pigs ( ); sensitized and antigen-stimulated vehicle-injected guinea-pigs ( ); nedocromil sodium (30 mg·kg⁻¹ daily for 5 days s.c.)-injected guinea-pigs ( ); or dexamethasone (20 mg·kg⁻¹ daily for 5 days s.c.)-injected guinea-pigs ( ). Results represent the number of positive cells per unit area of bronchial compartment (6.25×10⁴ µm²). Data are mean±SEM of 6–12 experiments. H159: monoclonal antibody for mature T-cells; H155: monoclonal antibody for CD4+ T-cells; CT6: monoclonal antibody for CD8+ T-cells. *: p<0.05, as compared to non-antigen-stimulated vehicle-tested animals; †: p<0.05, as compared to antigen stimulated vehicle-injected animals.

Fig. 4. – Distribution of eosinophil peroxidase (EPO)+ cells in the bronchial wall compartments a) lamina propria and b) adventitia from: sensitized non-antigen-stimulated vehicle-injected guinea-pigs ( ); sensitized and antigen-stimulated vehicle-injected guinea-pigs ( ); nedocromil sodium (30 mg·kg⁻¹ daily for 5 days s.c.)-injected guinea-pigs ( ); or dexamethasone (20 mg·kg⁻¹ daily for 5 days s.c.)-injected guinea-pigs ( ). Results represent the number of positive cells per unit area of bronchial compartment (6.25×10⁴ µm²). Data are mean±SEM of 6–12 experiments. *: p<0.05, as compared to non-antigen-stimulated vehicle-tested animals; †: p<0.05, as compared to antigen stimulated vehicle-injected animals.
Fig. 5. – Identification of T-lymphocytes (H159, alkaline phosphatase anti-alkaline phosphatase (APAAP)) in the bronchial lamina propria of sensitized non-antigen-stimulated or antigen-stimulated guinea-pigs. a) antigen-stimulated vehicle treated animal, showing intense T-lymphocyte infiltration; b) antigen-stimulated FK506-treated guinea-pig, with scant positive cells in the bronchial mucosa; c) antigen-stimulated nedocromil sodium-treated animal with many positive cells; d) dexamethasone-treated guinea-pig, again showing few positive cells in the bronchial submucosa. (Original magnification ×400; internal scale bar = 20 µm).

Fig. 6. – Lung sections from sensitized and antigen-stimulated guinea-pigs, stained for cyanide-resistant eosinophil peroxidase (EPO) activity. a) antigen-stimulated saline-treated animal, with numerous positive cells; b) antigen-stimulated FK506-treated guinea-pig, showing scant EPO⁺ cells in the bronchial mucosa; c) antigen-stimulated nedocromil sodium treated guinea-pig, with intense EPO⁺ cells infiltrating the bronchial mucosa; d) antigen-stimulated dexamethasone-treated animal, again showing few positive cells. (Original magnification ×400; internal scale bar = 20 µm).
Discussion

The present study demonstrates that FK506 has a profound effect on cellular infiltration into the bronchial compartments of sensitized guinea-pigs, and can completely curtail the inflammatory consequences of the booster injection of antigen. Even CD8$^+$ T-cells, although not substantially raised in the boosted animal, were reduced to levels below those of non-antigen-stimulated animals. The CD8$^+$ T-cell subset apparently plays a minor role in the allergic inflammation in this model. Both the present study and the results previously published [5] have consistently demonstrated that T-lymphocyte infiltration in the Airways of sensitized and boosted guinea-pigs is due solely to CD4$^+$ T-cells. Although CD8$^+$ T-cells did not increase in boosted animals as compared with their non-boosted counterparts, the fact that FK506 treatment reduced their levels below the numbers seen in non-boostered, vehicle-treated animals suggests a possible role for this subset in the allergic inflammation. However, it was beyond the aim of the present study to investigate the possible functional role of CD8$^+$ cells in the inflammation. Similarly, dexamethasone was able to abolish the inflammatory stimulus caused by the antigen stimulation in sensitized animals, demonstrated by a reduction in total T-cells, CD4$^+$ T-lymphocyte and eosinophil numbers to prebooster levels. CD8$^+$ T-cell numbers were also reduced in the bronchial adventitia, although not to the same level as after treatment with FK506. In contrast, nedocromil sodium was unable to interfere with the infiltration of the bronchial wall by FK506 in experimental conditions involving allergic inflammation [7]. FK506 prevents interleukin-2 (IL-2) production similarly to, but more effectively than, cyclosporin [12]. Many reports from the literature indicate that FK506 also inhibits the production of various cytokines [13, 14], and acts on mast cell function [15]. Hom and Estridge [16] also demonstrated that FK506 inhibits the production of granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) by human peripheral blood eosinophils upon stimulation with the calcium ionophore A23187. In contrast, FK506 had minimal effect on the interleukin-5 (IL-5)-mediated survival of eosinophils [16], suggesting that this drug interferes with the capacity of eosinophils to engage in events leading to chronic inflammation. Together, these findings encourage the use of FK506 in experimental conditions involving allergic inflammation and bronchial hyperresponsiveness. Fukuda et al., [17] have shown that FK506, when given to sensitized and challenged guinea-pigs from the beginning of the immunization period, was able to inhibit both bronchial hyperreactivity to acetylcholine and eosinophil infiltration into the tracheal wall. In a subsequent study, the authors used inhaled FK506 in sensitized guinea-pigs and found a striking reduction in eosinophil accumulation in the trachea, as well as in bronchial responsiveness to acetylcholine [18].

The clinical basis for the use of immunosuppressants in chronic asthma is glucocorticosteroid resistance, which is presented by a limited number of patients. In these circumstances, immunosuppressants, such as methotrexate, gold and cyclosporin A, have proved efficacious in controlling persistent symptoms [19]. Alexander et al., [20] performed a double-blind, cross-over study with cyclosporin A in patients with severe asthma and corticosteroid resistance and found amelioration, not only in clinical indices but also in functional parameters.

In the present study, we compared the effect of FK506 with that of well-established drugs. Dexamethasone showed an effect on the cellular parameters analysed similar to that of FK506. Nedocromil sodium failed to protect sensitized and antigen stimulated guinea-pigs from T-cell, CD4$^+$ T-lymphocyte or eosinophils recruitment. However, in a previous study, we demonstrated that nedocromil sodium, administered to sensitized guinea-pigs for 1 week after the booster injection of antigen, substantially reduced the enhanced platelet-activating factor (PAF)-induced bronchoconstriction and mediator release from isolated lungs, and inhibited hypereosinophilia in the bronchoalveolar compartment [6]. Many other reports have confirmed these findings in experimental models, showing marked effects of nedocromil sodium on airway responsiveness and eosinophilia, either bronchial or parenchymal [21, 22]. These experimental findings were corroborated by clinical studies, where the efficacy of nedocromil sodium in reducing symptoms and improving functional parameters was also seen [23]. However, none of these studies addressed the possible effects of nedocromil sodium on the T-lymphocyte infiltration in the bronchial mucosa, either in experimental models or clinical studies. In an in vitro study, O’Hehir and Moqbel [24] investigated the action of nedocromil sodium on specific allergen- or IL-2-induced proliferation of a human CD4$^+$ house dust mite-specific T-cell clone isolated from a patient with perennial rhinitis. No inhibitory effect was observed on proliferation indices in cultures treated with nedocromil sodium, but dexamethasone, in similar conditions, was able to inhibit the T-cell proliferation. The authors suggested that suppression of the late phase asthmatic response by nedocromil sodium may be due to mechanisms other than its action on CD4$^+$ T-lymphocytes.

There is circumstantial evidence that the association between activated T-lymphocytes, mainly of CD4$^+$ subset, and eosinophils play a major role in the development of the bronchial inflammation that accompanies bronchial hyperresponsiveness [3]. The presence of large numbers of T-cells, also of CD4$^+$ phenotype, and eosinophils were also reported in experimental models. These CD4$^+$ T-cells belong preferentially to the Th2 subset, secreting cytokines, such as IL-5, known to influence many aspects of the eosinophil biology. Neutralizing antibodies against IL-5 prevented eosinophil infiltration in the bronchial mucosa of allergic animals, and also blocked antigen-induced bronchial hyperresponsiveness [25]. FK506 and dexamethasone may, thus, prevent allergic airway inflammation not only via the reduction in the numbers of CD4$^+$ T-lymphocytes, but also possibly by blocking the production of relevant cytokines.
In conclusion, FK506 and dexamethasone were able to prevent the cellular response seen in the bronchial wall of sensitized and antigen stimulated guinea-pigs. Nedocromil sodium, however, did not interfere with mucosal eosinophilia and was unable to change the T-lymphocyte component of the allergic inflammation in this experimental model.

Acknowledgements: The authors are grateful to K. Murato (Fujisawa GmbH, Munich, Germany) for the gift of FK506, A. Norris (Fisons plc., Loughborough, UK) for the gift of nedocromil sodium, H. Schäffer and R. Burger (Robert-Koch Institute, Berlin, Germany) for providing the monoclonal antibodies H155 and H159, R. Scheper (Free University, Amsterdam, The Netherlands) for the gift of CT6, D. Baker (Royal College of Surgeons of England, London, UK) for helpful advice on the immunohistochemical techniques, and J. Lefort, for expert technical help. J.R. Lapa e Silva was partially funded by CEPG/UFRJ, FUJB, and CNPq.

References